Global X Autonomous & Electric Vehicles vs Mesoblast Limited — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.42, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| DRIV | MESO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $42.53 | $20.96 |
52-Week Low | $25.23 | $12.88 |
Market Cap | — | $2.16B |
Enterprise Value | — | $2.17B |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.78, up 2.55% today, with a bullish technical signal driven by moving averages. The stock shows strong year-to-date performance, supported by positive sentiment in the electric vehicle sector. Key support is at $35, with resistance at $36. Recent news highlights global EV sales growth and China's expanding market ambitions.
Outlook remains positive due to sector tailwinds and autonomous driving advancements, but risks include regulatory pressures and competitive threats from Chinese automakers. Institutional interest is strong, though overbought RSI signals caution near-term.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →